This study aimed to retrospectively evaluate the outcomes of the Pyrocardan® implant in patients aged 50 or younger who were treated for trapeziometacarpal osteoarthritis.

Fifty-six implants were assessed an average of 51 months postoperatively (24–157 months). The average patient age was 45 years old (17−50 years old).

Patients returned to work an average of 10 weeks postoperatively (2–24 weeks), regardless of whether they were heavy manual laborers.

The average strength was 6 kg for the key pinch and 27 kg for the grip.

The average pain score on a VAS, Q-Dash, and PRWE were 0.9, 16.6, and 16.7, respectively.

Overall, 94% of patients were satisfied, and the survival rate was 93%.

According to these results, the Pyrocardan® implant is an effective treatment for patients under 50 years old with disabling trapeziometacarpal osteoarthritis. It maintains mobility, provides pain relief, and restores strength comparable to the contralateral side, even for heavy manual laborers. In clinical and radiological terms, the tolerance of this implant remains consistent in the medium term. This confirms the reliability of the Pyrocardan® implant for treating trapeziometacarpal osteoarthritis in young, active patients.

IV, Observational case series.